Wolfgang Miesbach: Six Years of Normal Factor VIII After a Single Gene Therapy in Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Kerstin Herbst et al, published in Haemophilia:
“One single infusion.
Normal Factor VIII for six years – even after Grade 3 ALT elevation.
A new case report about a remarkable 6-year follow-up of a patient with severe haemophilia A treated with valoctocogene roxaparvovec within the GENEr8-1 study.
Six full years after a single gene therapy infusion, the patient maintains normal FVIII activity (49-72 IU/dL by chromogenic assay in year 6) – with zero bleeding episodes and no prophylactic FVIII infusions since treatment.
FVIII levels appear to have reached a plateau from year 3 onwards, pointing to durable, long-term transgene expression.
What makes this case particularly instructive is the immunosuppression management:
- Grade 3 ALT elevation (peak 555 U/L) at week 5 required hospitalisation and IV methyl-prednisolone
- Oral prednisolone was switched to budesonide to reduce systemic side effects (incl. oral thrush) – while FVIII levels remained protected
- Total immunosuppression lasted approximately 40 weeks – personalised, stepwise, and carefully tapered
For context: in the GENEr8-1 trial overall, only 8.3% of patients maintained FVIII more than 40 IU/dL at 5 years.
This case demonstrates that with tailored immunosuppression, significantly better long-term outcomes are within reach – even after a serious hepatic immune response.
Congratulations to Kerstin Herbst, Behnaz Pezeshkpoor and co-authors from the University of Bonn (Johannes Oldenburg).”
Title: Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels
Authors: Kerstin Herbst, Behnaz Pezeshkpoor, Claudia Klein, Thilo Albert, Philipp Lutz, Christian Strassburg, Ulrich Spengler, Georg Goldmann, Johannes Oldenburg
Read the Full Article on Haemophilia
Simon Fletcher, Research Assistant at University of Oxford, shared this post, adding:
“An interesting paper, but yet again, there is no discussion of the psychosocial impacts of either the gene therapy itself or the immunosuppression required to treat the ALT elevation.
Case reports are important but they should be more than just a report of the physical outcomes to a treatment or incident.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Apr 22, 2026, 14:51Mavis Agnes Kisakye: Reconnecting to Drive the Global Bleeding Disorders Agenda Forward
-
Apr 22, 2026, 14:48Augustina Isioma Ikusemoro: Not Every Antigen Speaks Loudly But the Right Test Will Hear It
-
Apr 22, 2026, 14:47Karuna Kumar: Busting the Myth about Increasing Infection Risk by IV Iron
-
Apr 22, 2026, 14:46David Brown: Charting a New Path Forward for One Patient Facing Extraordinary Cardiac Challenges
-
Apr 22, 2026, 14:45Ney Carter Borges: Syphilis and Cardiovascular Risk – A Silent and Progressive Vascular Burden
-
Apr 22, 2026, 14:44Sanjay Ahuja – New CEO and Medical Director of Innovative Hematology
-
Apr 22, 2026, 14:36Shivanand Kumatagi: Building Clinical Research Skills at the ASH CRTI Asia Pacific Program
-
Apr 22, 2026, 14:22Pradeep Natarajan: Can Polygenic Risk Scores Refine Risk Stratification in Secondary Prevention of CAD
-
Apr 22, 2026, 14:16Omar Adwan: Rare Genetic Disorders of Red Blood Cell Membrane Abnormalities